Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770805 | 1.00 | CASP3 (0.40) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL12601375 | 0.94 | CASP3 (0.41) | CASP3MDM4TP53KMT2ASLC17A5 | |
| SCHEMBL1410927 | 0.92 | CASP3 (0.46) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL1411037 | 0.92 | CASP3 (0.46) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2197673 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2197679 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2193892 | 0.89 | CASP3 (0.43) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2193899 | 0.89 | CASP3 (0.43) | CASP3MDM4TP53KMT2APTPN1 | |
| SCHEMBL2199165 | 0.87 | PTPN1 (0.44) | CASP3MDM4TP53PTPN1 | |
| SCHEMBL2199171 | 0.87 | PTPN1 (0.44) | CASP3MDM4TP53PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614193-B2 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LIMITED (GB) | 2013-12-24 | — | — | US | disclosed |
| EP-2293846-B1 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LTD (GB) | 2013-07-10 | — | — | EP | disclosed |
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | KARUS THERAPEUTICS LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | PRLHR, OPRD1, NPR3 | CASP3 1509/4885MDM4 4621/4885TP53 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.